|
|
Article: Novartis' Glivec granted priority review status by US FDA.(Clinical report)
- Article from:
- Pharma Marketletter
- Article date:
- September 1, 2008
CopyrightCOPYRIGHT 2008 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Swiss drug major Novartis' Glivec (imatinib) has been granted priority review status by the US Food and Drug Administration as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors. Similar regulatory submissions have been submitted in the European Union and Switzerland and will be filed in other countries shortly. The Glivec submissions are based on data from a ...